News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Roche bets $15B on obesity, IBD, cell therapy to escape biosimilar cliff
After losing $9.6B in peak oncology sales to biosimilars faster than forecast, Roche deployed $15B+ in two years across obesity, inflammatory bowel disease, and allogeneic CAR-T. Here's how the Swiss pharma is repositioning.
Drug makers need human liver data, not just better AI algorithms
Ochre Bio and Lexogen built one of the world's largest human liver datasets using gene knockouts across multiple donors. Here's why biology, not compute, is now the bottleneck.
Engineered Feeder Cells Expand NK Cancer Therapy Output 100,000-Fold
Modified ARH-77 feeder cells grew natural killer immune cells 101,241-fold in 28 days—150x better than the current standard. Why manufacturing bottlenecks in cell therapy are about to shift.
Biotech CEO: FDA overhaul and AI access are survival issues against China
BIO leader John Crowley warns that outdated clinical trial rules and unequal AI access threaten U.S. biotech dominance. He calls for regulatory modernization and policy fixes to close the gap with China.
First Huntington's Stem Cell Trial Enrolls Patient at UCI Health
UCI Health has begun the first human trial of embryonic stem cell-derived neural cells for Huntington's disease, using MRI-guided surgery to implant cells directly into the brain. The trial will enroll 21 patients and track safety and early signs of benefit.
UC San Diego finds drug target to restore cholesterol clearance
Researchers identified a protein called Ral that explains why high-cholesterol diets impair the liver's ability to clear LDL from blood. A drug candidate already tested for safety in humans could block this pathway.
InduPro Licenses Lonza's ADC Platform for Bispecific Cancer Therapies
InduPro gains access to Lonza's GlycoConnect, HydraSpace, and linker-payload technologies to combine with its bispecific antibody platform. The non-exclusive license targets up to two oncology antigens.
Novo, Genentech, Allogene shuffle exec teams amid strategy resets
Three major pharma players reshuffled their leadership in recent months. What the moves reveal about their competing bets on drug discovery, manufacturing, and cell therapy.
HHS fast-tracks U.S. drug trials to compete with China
The Department of Health and Human Services is streamlining early-stage clinical research to encourage pharma companies to run initial trials domestically instead of abroad. New reforms aim to recapture drug development that has shifted overseas.
Genes explain 79-94% of parent-child BMI link, study finds
Norwegian researchers analysed 86,000 children and found genetic factors account for most of the BMI correlation between parents and kids. What this means for obesity prevention strategies.
India sets first global standards for blood transfusion quality
Indian Pharmacopoeia 2026 introduces exclusive quality standards for blood and blood components—the first pharmacopoeia worldwide to do so. Blood centres must prepare for new compliance requirements.
Doctor with Ebola reaches Paris on commercial flight—WHO says global risk stays low
France confirmed its first Ebola case: a healthcare worker who flew from Congo with minimal symptoms. The WHO warns against panic while highlighting risks to frontline responders.